Darin Lippoldt
General Counsel at Neurocrine Biosciences Inc (NBIX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $4.2M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jul 13SEC | NBIXNeurocrine Biosciences Inc | Sell Plan | 10,00054,729 held (−15%) | $179.60 | $1.8M | -20.7% |
| Jun 30SEC | NBIXNeurocrine Biosciences Inc | Sell Plan | 20054,729 held (−0%) | $169.57 | $34K | -16.0% |
| Jun 30SEC | NBIXNeurocrine Biosciences Inc | Sell Plan | 8,11054,729 held (−13%) | $170.03 | $1.4M | -16.2% |
| Jun 30SEC | NBIXNeurocrine Biosciences Inc | Sell Plan | 1,69054,729 held (−3%) | $170.81 | $289K | -16.6% |
| Dec 10SEC | NBIXNeurocrine Biosciences Inc | Sell Plan | 4,37643,405 held (−9%) | $159.65 | $699K | -10.8% |
- Sell
General Counsel Darin Lippoldt sold $1.8M of NBIX at $179.60 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Darin Lippoldt sold $34K of NBIX at $169.57 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Darin Lippoldt sold $1.4M of NBIX at $170.03 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Darin Lippoldt sold $289K of NBIX at $170.81 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Darin Lippoldt sold $699K of NBIX at $159.65 — pre-scheduled 10b5-1 plan sale.